![Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Bristol-Myers Squibb) Drug Overview 2019- Product Image](http://www.researchandmarkets.com/product_images/8219/8219273_500px_jpg/market_research_report.jpg)
Drug Overview
Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva (efavirenz; Bristol-Myers Squibb) and two nucleos(t)ide reverse transcriptase inhibitors (NRTIs): Emtriva (emtricitabine; Gilead) and Viread (TDF; Gilead). NRTIs and NNRTIs block the action of the viral reverse transcriptase enzyme, preventing synthesis of viral DNA and subsequently inhibiting viral replication.
Since 2013, Atripla’s sales have entered a protracted decline as its patient share is gradually cannibalized by Gilead’s more recently launched single-tablet regimens, which have demonstrated superior central nervous system tolerability. Indeed, efavirenz’s poor tolerability profile has resulted in US and EU treatment guidelines downgrading Atripla from a “preferred” regimen to an “alternative” regimen, which has further hastened Atripla’s decline.
Analyst Outlook
Since 2013, Atripla’s ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead) sales have entered a protracted decline as its patient share is gradually cannibalized by Gilead’s more recently launched single-tablet regimens (STRs), which have demonstrated superior central nervous system tolerability. Indeed, efavirenz’s poor tolerability profile has resulted in US and EU treatment guidelines downgrading Atripla from a “preferred” regimen to an “alternative” regimen, which has further hastened Atripla’s decline. Additionally, since September 2017, Atripla’s sales have been severely threatened by the availability of generics, which have been heavily promoted by payers in order to reduce the growing cost burden of lifelong HIV treatment. Within the US, Atripla is not expected to lose exclusivity until September 2021, but by this time its use is expected to be minimal, as integrase strand transfer inhibitor-based and tenofovir alafenamide (TAF)-based STRs have largely replaced it in the first-line setting.
Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva (efavirenz; Bristol-Myers Squibb) and two nucleos(t)ide reverse transcriptase inhibitors (NRTIs): Emtriva (emtricitabine; Gilead) and Viread (TDF; Gilead). NRTIs and NNRTIs block the action of the viral reverse transcriptase enzyme, preventing synthesis of viral DNA and subsequently inhibiting viral replication.
Since 2013, Atripla’s sales have entered a protracted decline as its patient share is gradually cannibalized by Gilead’s more recently launched single-tablet regimens, which have demonstrated superior central nervous system tolerability. Indeed, efavirenz’s poor tolerability profile has resulted in US and EU treatment guidelines downgrading Atripla from a “preferred” regimen to an “alternative” regimen, which has further hastened Atripla’s decline.
Analyst Outlook
Since 2013, Atripla’s ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead) sales have entered a protracted decline as its patient share is gradually cannibalized by Gilead’s more recently launched single-tablet regimens (STRs), which have demonstrated superior central nervous system tolerability. Indeed, efavirenz’s poor tolerability profile has resulted in US and EU treatment guidelines downgrading Atripla from a “preferred” regimen to an “alternative” regimen, which has further hastened Atripla’s decline. Additionally, since September 2017, Atripla’s sales have been severely threatened by the availability of generics, which have been heavily promoted by payers in order to reduce the growing cost burden of lifelong HIV treatment. Within the US, Atripla is not expected to lose exclusivity until September 2021, but by this time its use is expected to be minimal, as integrase strand transfer inhibitor-based and tenofovir alafenamide (TAF)-based STRs have largely replaced it in the first-line setting.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
